Atika Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Atika Capital Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.48M	Sell	59,900 -32,606	-35%	-$1.5M	0.44%	51
2025 Q4	$4.15M	Buy	92,506 +54,506	+143%	+$2.29M	0.44%	63
2025 Q3	$1.53M	Buy	+38,000	New	+$1.34M	0.12%	79
2025 Q2	–	Sell	-24,000	Closed	-$805K	–	81
2025 Q1	$805K	Sell	24,000 -48,600	-67%	-$1.85M	0.11%	60
2024 Q4	$2.85M	Sell	72,600 -53,400	-42%	-$2.21M	0.3%	76
2024 Q3	$4.96M	Buy	126,000 +2,000	+2%	+$80.6K	0.51%	59
2024 Q2	$4.83M	Buy	124,000 +2,000	+2%	+$79.9K	0.47%	64
2024 Q1	$5.25M	Buy	122,000 +28,766	+31%	+$1.32M	0.52%	66
2023 Q4	$4.29M	Buy	+93,234	New	+$3.29M	0.58%	60
2023 Q3	–	Sell	-68,050	Closed	-$2.62M	–	104
2023 Q2	$2.62M	Buy	68,050 +600	+0.9%	+$23.9K	0.26%	75
2023 Q1	$2.41M	Buy	+67,450	New	+$2.49M	0.36%	64

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Atika Capital Management's XENE Position: Q1 2026 in Review

Atika Capital Management reduced its Xenon Pharmaceuticals (XENE) stake by 35% in Q1 2026, selling an estimated $1.5M and leaving 59,900 shares worth $3.48M. The position accounts for 0.44% of the portfolio, ranked #51.

Atika Capital Management first reported a position in XENE in Q1 2023 and has held it in 11 quarters since. The position peaked at $5.25M in Q1 2024. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

Atika Capital Management held 59,900 shares of Xenon Pharmaceuticals worth $3.48M as of Q1 2026.
Atika Capital Management sold 32,606 Xenon Pharmaceuticals shares in Q1 2026, an estimated $1.5M.
Xenon Pharmaceuticals made up 0.44% of Atika Capital Management's portfolio in Q1 2026, its #51 holding.
Atika Capital Management first reported a position in Xenon Pharmaceuticals in Q1 2023 and has held it in 11 quarters since.
Atika Capital Management's Xenon Pharmaceuticals position peaked at $5.25M in Q1 2024.
290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Atika Capital Management's 13F filing for Q1 2026, filed 14 May 2026.